Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022GlobeNewsWire • 08/25/22
Clearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/09/22
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 MillionGlobeNewsWire • 08/08/22
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022GlobeNewsWire • 08/03/22
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022GlobeNewsWire • 07/27/22
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD PatientsGlobeNewsWire • 07/26/22
Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical MeetingsGlobeNewsWire • 07/07/22
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical OfficerGlobeNewsWire • 06/14/22
Clearside Biomedical to Participate in the JMP Securities Life Sciences ConferenceGlobeNewsWire • 06/08/22
Clearside Biomedical, Inc.'s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/22
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery TechnologyGlobeNewsWire • 05/05/22
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022GlobeNewsWire • 04/29/22
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with UveitisPRNewsWire • 03/28/22
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/11/22
Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 03/10/22
Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/10/22
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022GlobeNewsWire • 03/01/22